Kiniksa Pharmaceuticals to Present at Bank of America Securities 2022 Biotech SMID Cap Conference

Rhea-AI Summary

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced participation in the Bank of America Securities 2022 Biotech SMID Cap Conference, set for December 7, 2022, at 10:15 a.m. Eastern Time. This event will feature a fireside chat with management. Investors can access a live webcast via the company's website, with a replay available approximately 48 hours post-event. Kiniksa is dedicated to developing therapeutic medicines for serious diseases and boasts a portfolio that includes ARCALYST®, KPL-404, and mavrilimumab.

HAMILTON, Bermuda, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Bank of America Securities 2022 Biotech SMID Cap Conference on Wednesday, December 7, 2022 at 10:15 a.m. Eastern Time.

A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio assets, ARCALYST^®, KPL-404, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.

ARCALYST^® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts! ® Kiniksa Investor and Media Contact Rachel Frank (339) 970-9437 rfrank@kiniksa.com

FAQ

What event is Kiniksa Pharmaceuticals participating in?

Kiniksa Pharmaceuticals is participating in the Bank of America Securities 2022 Biotech SMID Cap Conference on December 7, 2022.

What time will Kiniksa's presentation take place?

Kiniksa's presentation is scheduled for 10:15 a.m. Eastern Time on December 7, 2022.

How can I watch Kiniksa's presentation at the conference?

You can watch Kiniksa's presentation live through the Investors & Media section of their website.

Will there be a replay of Kiniksa's conference presentation?

Yes, a replay of Kiniksa's presentation will be available on their website within approximately 48 hours after the event.

What are Kiniksa Pharmaceuticals' main therapeutic assets?

Kiniksa's main therapeutic assets include ARCALYST®, KPL-404, and mavrilimumab.

What is the focus of Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals focuses on developing therapeutic medicines for patients with significant unmet medical needs.